연구성과로 돌아가기

2023 연구성과별 연구자 정보 (719 / 2675)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Ojha, Uttam Ojha, U 2 Kyungpook Natl Univ, Coll Pharm, Natl Basic Res Lab Vasc Homeostasis Regulat, 80 Daehakro, Daegu 41566, South Korea 0000-0002-2938-5595 Ojha, Uttam lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Ojha, Uttam Ojha, U 2 Kyungpook Natl Univ, Coll Pharm, 80 Daehakro, Daegu 41566, South Korea 0000-0002-2938-5595 Ojha, Uttam lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Jang, Hyeonha Jang, H 3 Kyungpook Natl Univ, Vessel Organ Interact Res Ctr VOICE MRC, Daegu 41566, South Korea lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Jang, Hyeonha Jang, H 3 Kyungpook Natl Univ, Coll Pharm, Natl Basic Res Lab Vasc Homeostasis Regulat, 80 Daehakro, Daegu 41566, South Korea lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Jang, Hyeonha Jang, H 3 Kyungpook Natl Univ, Coll Pharm, 80 Daehakro, Daegu 41566, South Korea lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Kang, Soohyun Kang, S 4 Kyungpook Natl Univ, Coll Pharm, Natl Basic Res Lab Vasc Homeostasis Regulat, 80 Daehakro, Daegu 41566, South Korea lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Kang, Soohyun Kang, S 4 Kyungpook Natl Univ, Coll Pharm, 80 Daehakro, Daegu 41566, South Korea lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Lee, Sunhee Lee, S 5 Kyungpook Natl Univ, Vessel Organ Interact Res Ctr VOICE MRC, Daegu 41566, South Korea C-9016-2011 Lee, Kyung-Soo lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Lee, Sunhee Lee, S 5 Kyungpook Natl Univ, Coll Pharm, 80 Daehakro, Daegu 41566, South Korea C-9016-2011 Lee, Kyung-Soo lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Lee, You Mie Lee, YM 6 교신저자 Kyungpook Natl Univ, Vessel Organ Interact Res Ctr VOICE MRC, Daegu 41566, South Korea lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Lee, You Mie Lee, YM 6 교신저자 Kyungpook Natl Univ, Coll Pharm, Natl Basic Res Lab Vasc Homeostasis Regulat, 80 Daehakro, Daegu 41566, South Korea lym@knu.ac.kr;
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin Lee, You Mie Lee, YM 6 교신저자 Kyungpook Natl Univ, Coll Pharm, 80 Daehakro, Daegu 41566, South Korea lym@knu.ac.kr;
Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN Cohen, S. Cohen, S 1 Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Pediat Gastroenterol Inst, Tel Aviv, Israel
Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN Cohen, S. Cohen, S 1 Tel Aviv Univ, Pediat Gastroenterol Inst, Sackler Fac Med, Tel Aviv, Israel
Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN Olbjorn, C. Olbjorn, C 2 Akershus Univ Hosp, Dept Paediat & Adolescent Med, Lorenskog, Norway
페이지 이동: